NYSE:ABT - Abbott Laboratories Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $115.38
  • Forecasted Upside: 7.22 %
  • Number of Analysts: 18
  • Breakdown:
  • 1 Sell Ratings
  • 4 Hold Ratings
  • 13 Buy Ratings
  • 0 Strong Buy Ratings
$107.61
▼ -1.66 (-1.52%)
1 month | 3 months | 12 months
Get New Abbott Laboratories Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ABT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ABT

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$115.38
▲ +7.22% Upside Potential
This price target is based on 18 analysts offering 12 month price targets for Abbott Laboratories in the last 3 months. The average price target is $115.38, with a high forecast of $130.00 and a low forecast of $94.00. The average price target represents a 7.22% upside from the last price of $107.61.
Buy
The current consensus among 18 polled investment analysts is to buy stock in Abbott Laboratories. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 15 buy ratings
  • 2 hold ratings
  • 2 sell ratings
6/3/2019
  • 0 strong buy ratings
  • 14 buy ratings
  • 2 hold ratings
  • 2 sell ratings
9/1/2019
  • 0 strong buy ratings
  • 12 buy ratings
  • 2 hold ratings
  • 2 sell ratings
11/30/2019
  • 0 strong buy ratings
  • 13 buy ratings
  • 3 hold ratings
  • 2 sell ratings
2/28/2020
  • 0 strong buy ratings
  • 14 buy ratings
  • 4 hold ratings
  • 2 sell ratings
5/28/2020
  • 0 strong buy ratings
  • 11 buy ratings
  • 4 hold ratings
  • 2 sell ratings
8/26/2020
  • 0 strong buy ratings
  • 13 buy ratings
  • 4 hold ratings
  • 1 sell ratings
10/25/2020
  • 0 strong buy ratings
  • 13 buy ratings
  • 4 hold ratings
  • 1 sell ratings
11/24/2020

Latest Recommendations

  • 0 strong buy ratings
  • 13 buy ratings
  • 4 hold ratings
  • 1 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/19/2020Morgan StanleyBoost Price TargetOverweight$117.00 ➝ $121.00Low
i
10/22/2020Jefferies Financial GroupBoost Price TargetBuy$113.00 ➝ $123.00High
i
10/22/2020Credit Suisse GroupLower Price TargetOutperform$136.00 ➝ $118.00High
i
Rating by Matt Miksic at Credit Suisse Group AG
10/22/2020Raymond JamesBoost Price TargetMarket Perform ➝ Outperform$102.00 ➝ $114.00High
i
10/22/2020Morgan StanleyBoost Price TargetOverweight$112.00 ➝ $117.00High
i
10/22/2020SVB LeerinkBoost Price TargetPositive ➝ Market Perform$110.00 ➝ $115.00High
i
10/9/2020JPMorgan Chase & Co.Boost Price TargetOverweight$110.00 ➝ $125.00Low
i
10/7/2020Wells Fargo & CompanyBoost Price TargetOverweight$120.00 ➝ $122.00Low
i
Rating by Larry Biegelsen at Wells Fargo & Company
9/11/2020Wolfe ResearchInitiated CoverageOutperform$124.00Low
i
9/2/2020The Goldman Sachs GroupSet Price TargetSell$94.00Low
i
Rating by Amit Hazan at The Goldman Sachs Group, Inc.
8/31/2020Credit Suisse GroupBoost Price TargetOutperform$109.00 ➝ $136.00Low
i
Rating by Matt Miksic at Credit Suisse Group AG
8/28/2020CitigroupBoost Price TargetBuy$110.00 ➝ $130.00High
i
8/27/2020BTIG ResearchReiterated RatingHoldHigh
i
Rating by Marie Thibault at BTIG Research
8/27/2020The Goldman Sachs GroupSet Price TargetSell$94.00Medium
i
Rating by Amit Hazan at The Goldman Sachs Group, Inc.
8/27/2020Wells Fargo & CompanyBoost Price Target$107.00 ➝ $115.00Medium
i
Rating by Larry Biegelsen at Wells Fargo & Company
8/27/2020Stifel NicolausBoost Price TargetBuy$108.00 ➝ $115.00Low
i
8/27/2020Morgan StanleyBoost Price TargetOverweight$106.00 ➝ $112.00Medium
i
7/23/2020ArgusBoost Price Target$110.00 ➝ $125.00Low
i
7/20/2020Bank of AmericaBoost Price TargetBuy$95.00 ➝ $110.00Medium
i
7/17/2020SVB LeerinkBoost Price TargetMarket Perform$97.00 ➝ $110.00High
i
7/17/2020Morgan StanleyBoost Price TargetOverweight$100.00 ➝ $106.00High
i
7/17/2020Credit Suisse GroupBoost Price TargetOutperform$106.00 ➝ $109.00High
i
Rating by Matt Miksic at Credit Suisse Group AG
7/17/2020CitigroupBoost Price TargetBuy$109.00 ➝ $110.00Medium
i
7/9/2020Wells Fargo & CompanyReiterated RatingBuy$107.00Low
i
Rating by Larry Biegelsen at Wells Fargo & Company
6/25/2020Morgan StanleyLower Price TargetOverweight$108.00 ➝ $100.00High
i
5/31/2020The Goldman Sachs GroupDowngradeNeutral ➝ Sell$84.00Medium
i
5/22/2020Credit Suisse GroupReiterated RatingBuy$106.00Low
i
Rating by Matt Miksic at Credit Suisse Group AG
4/20/2020BarclaysBoost Price TargetOverweight$92.00 ➝ $100.00Medium
i
4/17/2020UBS GroupBoost Price TargetBuy$105.00 ➝ $109.00Low
i
4/17/2020JPMorgan Chase & Co.Boost Price TargetOverweight$88.00 ➝ $98.00Low
i
4/17/2020Stifel NicolausBoost Price Target$85.00 ➝ $108.00Low
i
4/17/2020Credit Suisse GroupBoost Price TargetOutperform$95.00 ➝ $106.00Medium
i
Rating by Matt Miksic at Credit Suisse Group AG
4/17/2020Raymond JamesBoost Price TargetOverweight ➝ Outperform$92.00 ➝ $102.00Low
i
4/17/2020CitigroupBoost Price TargetBuy$87.00 ➝ $109.00Medium
i
4/17/2020Wells Fargo & CompanyBoost Price TargetOverweight$95.00 ➝ $107.00Medium
i
4/16/2020BTIG ResearchReiterated RatingHoldLow
i
Rating by Marie Thibault at BTIG Research
4/16/2020CfraBoost Price TargetBuy$99.00 ➝ $101.00Low
i
4/9/2020Wells Fargo & CompanyBoost Price TargetOverweight$92.00 ➝ $95.00Medium
i
4/9/2020Raymond JamesLower Price TargetOutperform$99.00 ➝ $92.00Medium
i
4/8/2020Wells Fargo & CompanyReiterated RatingBuyMedium
i
4/8/2020SVB LeerinkLower Price TargetMarket Perform$102.00 ➝ $93.00High
i
4/3/2020JPMorgan Chase & Co.Lower Price TargetOverweight$101.00 ➝ $88.00Low
i
3/30/2020Wells Fargo & CompanyReiterated RatingBuyMedium
i
3/27/2020CitigroupLower Price TargetBuy$96.00 ➝ $87.00Medium
i
3/27/2020Morgan StanleyLower Price TargetOverweight$101.00 ➝ $96.00Medium
i
3/6/2020Credit Suisse GroupLower Price TargetOutperform$104.00 ➝ $94.00High
i
3/4/2020CitigroupInitiated CoverageBuy$96.00Medium
i
2/12/2020The Goldman Sachs GroupInitiated CoverageNeutral$96.00Low
i
2/6/2020BTIG ResearchReiterated RatingHoldLow
i
1/23/2020JPMorgan Chase & Co.Lower Price Target$96.00 ➝ $101.00Low
i
1/23/2020UBS GroupBoost Price TargetBuy$99.00 ➝ $105.00Low
i
1/23/2020Wells Fargo & CompanyBoost Price TargetOverweight$97.00 ➝ $103.00Medium
i
1/23/2020Raymond JamesBoost Price TargetOutperform$90.00 ➝ $99.00Medium
i
1/23/2020Stifel NicolausBoost Price TargetBuy$95.00 ➝ $104.00Medium
i
1/2/2020CitigroupDowngradeNeutral ➝ SellHigh
i
1/2/2020Evercore ISIDowngradeOutperform ➝ In-LineHigh
i
1/2/2020GuggenheimDowngradeBuy ➝ NeutralMedium
i
12/17/2019Morgan StanleyBoost Price TargetOverweight$93.00 ➝ $101.00Medium
i
10/17/2019William BlairReiterated RatingUnderperformLow
i
Rating by M. Kaczor at William Blair
10/17/2019Credit Suisse GroupBoost Price TargetOutperform$95.00 ➝ $98.00Low
i
10/14/2019Raymond JamesLower Price TargetOutperform$93.00 ➝ $90.00Low
i
7/18/2019Jefferies Financial GroupBoost Price TargetBuy$80.00 ➝ $98.00Medium
i
7/18/2019CowenBoost Price TargetOutperform$86.00 ➝ $95.00High
i
7/18/2019Raymond JamesBoost Price TargetOutperform$87.00 ➝ $93.00Medium
i
7/18/2019BMO Capital MarketsBoost Price TargetOutperform$87.00 ➝ $94.00Medium
i
7/16/2019Morgan StanleyBoost Price TargetOverweight$85.00 ➝ $93.00Low
i
6/13/2019Bank of AmericaReiterated RatingBuy$81.00Low
i
6/13/2019Wells Fargo & CompanyBoost Price TargetOutperform$89.00 ➝ $91.00Low
i
4/18/2019William BlairReiterated RatingOutperformN/A
i
Rating by M. Kaczor at William Blair
4/15/2019Royal Bank of CanadaBoost Price TargetBuy$82.00Low
i
3/14/2019Wells Fargo & CompanyReiterated RatingBuyHigh
i
3/8/2019BarclaysSet Price TargetBuy$84.00Low
i
Rating by Kristen Stewart at Barclays PLC
2/7/2019Bank of AmericaReiterated RatingBuy ➝ Buy$73.00 ➝ $81.00Low
i
1/25/2019ArgusBoost Price TargetBuy ➝ In-Line$90.00Low
i
1/24/2019BTIG ResearchReiterated RatingHoldMedium
i
1/2/2019GabelliReiterated RatingBuyLow
i
Rating by J. Tsai at Gabelli
1/2/2019Morgan StanleyBoost Price TargetOverweight ➝ Overweight$82.00 ➝ $85.00Low
i
1/2/2019CitigroupDowngradeNeutral ➝ Sell$72.00 ➝ $68.00High
i
12/17/2018Credit Suisse GroupInitiated CoverageOutperform$82.00Low
i
12/9/2018The Goldman Sachs GroupUpgradeNeutral ➝ Buy$74.10Low
i
Rating by Issac Ro at The Goldman Sachs Group, Inc.
12/4/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$80.00 ➝ $82.00High
i
11/30/2018The Goldman Sachs GroupUpgradeNeutral ➝ Buy$78.00 ➝ $81.00Low
i
Rating by Isaac Ro at The Goldman Sachs Group, Inc.
11/27/2018UBS GroupInitiated CoverageBuy$83.00High
i
10/18/2018Jefferies Financial GroupReiterated RatingIn-Line ➝ Buy$80.00High
i
10/18/2018Raymond JamesBoost Price TargetOutperform ➝ Outperform$77.00 ➝ $79.00High
i
10/18/2018BTIG ResearchReiterated RatingHoldHigh
i
10/15/2018BarclaysInitiated CoverageOverweight ➝ Overweight$80.00High
i
10/11/2018Morgan StanleyBoost Price TargetOverweight$70.00 ➝ $80.00Medium
i
10/11/2018Royal Bank of CanadaBoost Price TargetOutperform$77.00Low
i
10/8/2018JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$77.00 ➝ $81.00Low
i
10/5/2018CowenBoost Price TargetOutperform ➝ Average$72.00 ➝ $86.00Low
i
9/24/2018Raymond JamesBoost Price TargetOutperform ➝ Outperform$72.00 ➝ $77.00Medium
i
9/24/2018Wells Fargo & CompanyBoost Price TargetOutperform ➝ Outperform$77.00 ➝ $80.00Medium
i
7/19/2018Royal Bank of CanadaReiterated RatingBuy$70.00Low
i
7/19/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$71.00 ➝ $72.00Medium
i
6/27/2018Sanford C. BernsteinInitiated CoverageOutperform$73.00Medium
i
4/24/2018CitigroupLower Price TargetNeutral ➝ Neutral$66.00 ➝ $65.00Low
i
4/22/2018BTIG ResearchReiterated RatingHoldLow
i
1/30/2018ArgusBoost Price TargetBuy$66.00 ➝ $80.00Low
i
1/30/2018CitigroupBoost Price TargetNeutral ➝ Neutral$59.00 ➝ $64.00Low
i
1/25/2018BarclaysBoost Price TargetOverweight ➝ Overweight$66.00 ➝ $70.00Low
i
1/25/2018GuggenheimReiterated RatingBuy$72.00Low
i
1/25/2018Royal Bank of CanadaReiterated RatingBuy$67.00Low
i
1/25/2018SVB LeerinkReiterated RatingMarket Perform$60.00 ➝ $68.00Low
i
Rating by D. Antalffy at SVB Leerink LLC
1/25/2018JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$65.00 ➝ $69.00High
i
1/25/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$67.00 ➝ $70.00High
i
1/25/2018Wells Fargo & CompanyBoost Price TargetOutperform$66.00 ➝ $70.00Medium
i
1/25/2018BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$65.00 ➝ $70.00Medium
i
1/25/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$63.00 ➝ $71.00Medium
i
1/25/2018William BlairUpgradeMarket Perform ➝ OutperformMedium
i
Rating by M. Kaczor at William Blair
1/24/2018Bank of AmericaBoost Price Target$60.00 ➝ $70.00High
i
1/22/2018BTIG ResearchDowngradeBuy ➝ NeutralMedium
i
1/19/2018SVB LeerinkReiterated RatingMarket PerformLow
i
Rating by D. Antalffy at SVB Leerink LLC
1/9/2018Royal Bank of CanadaReiterated RatingBuy$65.00Low
i
1/8/2018BarclaysReiterated RatingBuy$66.00Low
i
1/3/2018Evercore ISIInitiated CoverageOutperform ➝ Outperform$64.00Low
i
1/2/2018JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$60.00 ➝ $60.00Low
i
1/2/2018Morgan StanleyUpgradeEqual Weight ➝ Overweight$67.00Low
i
12/12/2017BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$58.00 ➝ $65.00Medium
i
10/19/2017BarclaysReiterated RatingOverweightN/A
i
10/19/2017CitigroupReiterated RatingNeutralN/A
i
10/19/2017BMO Capital MarketsReiterated RatingMarket PerformN/A
i
10/19/2017CowenSet Price TargetBuy$55.00 ➝ $68.00N/A
i
10/19/2017Stifel NicolausBoost Price TargetBuy ➝ Buy$58.00 ➝ $63.00N/A
i
10/19/2017Royal Bank of CanadaBoost Price TargetOutperform ➝ Outperform$55.00 ➝ $60.00N/A
i
10/19/2017Jefferies Financial GroupReiterated RatingBuy$65.00N/A
i
10/6/2017JPMorgan Chase & Co.Initiated CoverageNeutral ➝ Neutral$60.00N/A
i
10/4/2017Bank of AmericaReiterated RatingBuy$56.00 ➝ $60.00N/A
i
10/3/2017Royal Bank of CanadaReiterated RatingBuy$55.00Low
i
10/2/2017BMO Capital MarketsReiterated RatingHold$53.00Low
i
9/28/2017BarclaysBoost Price TargetOverweight$57.00 ➝ $60.00Low
i
9/28/2017Wells Fargo & CompanyBoost Price TargetOutperform$57.00 ➝ $64.00Low
i
9/24/2017CowenReiterated RatingBuyLow
i
Rating by Josh Jennings at Cowen Inc
9/1/2017BMO Capital MarketsReiterated RatingHold$53.00N/A
i
8/17/2017CitigroupInitiated CoverageNeutral ➝ Neutral$53.00Medium
i
8/17/2017CowenReiterated RatingBuy$55.00Medium
i
Rating by Josh Jennings at Cowen Inc
8/3/2017Jefferies Financial GroupReiterated RatingBuy$58.00Low
i
7/22/2017BarclaysReiterated RatingOverweight$52.00 ➝ $57.00Low
i
7/21/2017Stifel NicolausReiterated RatingBuy$58.00Low
i
7/14/2017CowenReiterated RatingOutperform$48.00 ➝ $55.00Low
i
Rating by Josh Jennings at Cowen Inc
7/11/2017BMO Capital MarketsReiterated RatingHold$48.00Low
i
7/10/2017Morgan StanleyReiterated RatingEqual WeightLow
i
6/30/2017Wells Fargo & CompanyReiterated RatingOutperform$47.50 ➝ $54.00Low
i
6/29/2017Jefferies Financial GroupReiterated RatingBuy$58.00Low
i
6/29/2017GuggenheimInitiated CoverageBuy$58.00Low
i
6/21/2017BTIG ResearchReiterated RatingBuy$56.00Low
i
6/16/2017Jefferies Financial GroupReiterated RatingBuy$55.00Low
i
5/31/2017Stifel NicolausBoost Price TargetBuy$49.00 ➝ $51.00Medium
i
5/16/2017The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$45.00Low
i
5/15/2017Royal Bank of CanadaReiterated RatingBuyLow
i
5/12/2017Jefferies Financial GroupReiterated RatingBuy$50.00 ➝ $51.00Low
i
4/22/2017CowenReiterated RatingOutperform$48.00Medium
i
Rating by Josh Jennings at Cowen Inc
4/20/2017BarclaysBoost Price TargetOverweight ➝ Overweight$50.00 ➝ $52.00Low
i
4/19/2017Morgan StanleyReiterated RatingEqual Weight$42.00Low
i
4/18/2017UBS GroupReiterated RatingNeutral$41.00N/A
i
4/18/2017Jefferies Financial GroupLower Price TargetBuy$52.00 ➝ $50.00Medium
i
4/18/2017Stifel NicolausReiterated RatingBuy$49.00Medium
i
4/13/2017CowenReiterated RatingBuy$48.00Low
i
Rating by Josh Jennings at Cowen Inc
3/14/2017BMO Capital MarketsDowngradeOutperform ➝ Market Perform$48.00Medium
i
3/11/2017Jefferies Financial GroupReiterated RatingBuy$51.00 ➝ $52.00N/A
i
3/1/2017Royal Bank of CanadaBoost Price TargetOutperform$46.00 ➝ $50.00N/A
i
2/17/2017Jefferies Financial GroupReiterated RatingBuy$51.00N/A
i
1/26/2017Royal Bank of CanadaLower Price TargetOutperform$48.00 ➝ $46.00N/A
i
1/20/2017Jefferies Financial GroupBoost Price TargetBuy$47.00 ➝ $48.00N/A
i
1/13/2017Jefferies Financial GroupBoost Price TargetBuy$46.00 ➝ $47.00N/A
i
Rating by Jeffrey Holford at Jefferies Financial Group Inc.
12/20/2016Jefferies Financial GroupReiterated RatingBuy$46.00N/A
i
Rating by Jeffrey Holford at Jefferies Financial Group Inc.
9/19/2016Bank of AmericaReiterated RatingBuyN/A
i
9/19/2016Royal Bank of CanadaReiterated RatingOutperform$48.00N/A
i
Rating by Glenn Novarro at Royal Bank of Canada
9/13/2016Jefferies Financial GroupLower Price TargetBuy$52.00 ➝ $48.00N/A
i
Rating by Jeffrey Holford at Jefferies Financial Group Inc.
8/12/2016Bank of AmericaReiterated RatingBuy$50.00N/A
i
8/10/2016BTIG ResearchReiterated RatingBuy$45.00N/A
i
Rating by Dane Leone at BTIG Research
8/9/2016Deutsche Bank AktiengesellschaftReiterated RatingBuyN/A
i
Rating by Kristen Stewart at Deutsche Bank Aktiengesellschaft
8/4/2016Jefferies Financial GroupBoost Price TargetBuy$49.00 ➝ $52.00N/A
i
Rating by Jeffrey Holford at Jefferies Financial Group Inc.
7/28/2016ArgusReiterated RatingBuy$55.00N/A
i
7/21/2016BarclaysBoost Price TargetOverweight$48.00 ➝ $50.00N/A
i
Rating by Matthew Taylor at Barclays PLC
7/21/2016UBS GroupReiterated RatingHold$45.00N/A
i
7/14/2016Jefferies Financial GroupBoost Price TargetBuy$45.00 ➝ $49.00N/A
i
Rating by Jeffrey Holford at Jefferies Financial Group Inc.
7/12/2016BarclaysReiterated RatingOverweight$48.00N/A
i
Rating by Matthew Taylor at Barclays PLC
6/21/2016Edward JonesUpgradeHold ➝ BuyN/A
i
6/18/2016BarclaysReiterated RatingBuy$48.00N/A
i
Rating by Matthew Taylor at Barclays PLC
6/14/2016Jefferies Financial GroupBoost Price TargetBuy$44.00 ➝ $45.00N/A
i
Rating by Jeffrey Holford at Jefferies Financial Group Inc.
6/8/2016Credit Suisse GroupReiterated RatingBuyN/A
i
Rating by Matthew Keeler at Credit Suisse Group AG
5/13/2016Jefferies Financial GroupReiterated RatingBuy$44.00N/A
i
Rating by Jeffrey Holford at Jefferies Financial Group Inc.
5/12/2016Wells Fargo & CompanyReiterated RatingBuyN/A
i
Rating by Larry Biegelsen at Wells Fargo & Company
5/2/2016BMO Capital MarketsReiterated RatingBuyN/A
i
4/30/2016Jefferies Financial GroupReiterated RatingBuyN/A
i
Rating by Jeffrey Holford at Jefferies Financial Group Inc.
4/30/2016Credit Suisse GroupReiterated RatingBuyN/A
i
Rating by Matthew Keeler at Credit Suisse Group AG
4/30/2016S&P Equity ResearchReiterated RatingHoldN/A
i
Rating by Jeffrey Loo at S&P Equity Research
4/30/2016Wells Fargo & CompanyReiterated RatingBuyN/A
i
Rating by Larry Biegelsen at Wells Fargo & Company
4/30/2016GabelliReiterated RatingBuyN/A
i
Rating by Jennie Tsai at Gabelli
4/28/2016BTIG ResearchReiterated RatingBuy$45.00N/A
i
Rating by Dane Leone at BTIG Research
4/28/2016Piper Jaffray CompaniesDowngradeOverweight ➝ NeutralN/A
i
4/21/2016CowenReiterated RatingNeutral ➝ Buy$44.00 ➝ $48.00N/A
i
Rating by Josh Jennings at Cowen Inc
4/20/2016BTIG ResearchReiterated RatingBuy$45.00N/A
i
Rating by Dane Leone at BTIG Research
4/17/2016Credit Suisse GroupReiterated RatingBuyN/A
i
Rating by Matthew Keeler at Credit Suisse Group AG
4/14/2016First GlobalDowngradeOutperform ➝ MarketperformN/A
i
Rating by K. Thomas at First Global
4/11/2016Royal Bank of CanadaReiterated RatingOutperform$45.00 ➝ $48.00N/A
i
3/28/2016Stifel NicolausBoost Price TargetBuy$42.00 ➝ $47.00N/A
i
3/28/2016SVB LeerinkBoost Price TargetMarket Perform$37.00 ➝ $40.00N/A
i
3/28/2016BMO Capital MarketsBoost Price TargetOutperform$42.00 ➝ $45.00N/A
i
3/19/2016Deutsche Bank AktiengesellschaftReiterated RatingBuyN/A
i
Rating by Kristen Stewart at Deutsche Bank Aktiengesellschaft
3/16/2016BTIG ResearchReiterated RatingBuy$45.00N/A
i
Rating by Dane Leone at BTIG Research
3/15/2016Jefferies Financial GroupReiterated RatingBuy$45.00 ➝ $47.00N/A
i
Rating by Jeffrey Holford at Jefferies Financial Group Inc.
3/15/2016Credit Suisse GroupReiterated RatingOutperform$47.00N/A
i
2/22/2016Jefferies Financial GroupLower Price TargetBuy$45.00N/A
i
Rating by Jeffrey Holford at Jefferies Financial Group Inc.
2/5/2016ArgusUpgradeHold ➝ Buy$50.00N/A
i
2/1/2016UBS GroupReiterated RatingNeutralN/A
i
1/31/2016BTIG ResearchReiterated RatingBuy$45.00N/A
i
Rating by Dane Leone at BTIG Research
1/31/2016SVB LeerinkLower Price TargetMarket Perform$46.00 ➝ $40.00N/A
i
1/30/2016BMO Capital MarketsLower Price TargetOutperform$48.00 ➝ $45.00N/A
i
1/29/2016Stifel NicolausLower Price Target$58.00 ➝ $47.00N/A
i
1/29/2016Raymond JamesLower Price TargetOutperform$46.00 ➝ $42.00N/A
i
1/29/2016The Goldman Sachs GroupLower Price TargetNeutral$44.00 ➝ $40.00N/A
i
1/29/2016Deutsche Bank AktiengesellschaftReiterated RatingBuyN/A
i
Rating by Kristen Stewart at Deutsche Bank Aktiengesellschaft
1/29/2016Royal Bank of CanadaLower Price TargetOutperform$51.00 ➝ $45.00N/A
i
Rating by Glenn Novarro at Royal Bank of Canada
1/29/2016William BlairDowngradeOutperform ➝ Market PerformN/A
i
Rating by M. Kaczor at William Blair
1/27/2016Jefferies Financial GroupLower Price TargetBuy$50.00 ➝ $47.00N/A
i
Rating by Jeffrey Holford at Jefferies Financial Group Inc.
1/25/2016SVB LeerinkLower Price TargetMarket Perform$50.00 ➝ $46.00N/A
i
1/24/2016BMO Capital MarketsLower Price TargetOutperform$48.00 ➝ $45.00N/A
i
1/14/2016Jefferies Financial GroupLower Price TargetBuy$55.00 ➝ $50.00N/A
i
Rating by Jeffrey Holford at Jefferies Financial Group Inc.
1/5/2016Bank of AmericaReiterated RatingBuy$53.00N/A
i
1/4/2016Morgan StanleyDowngradeOverweight ➝ Equal Weight$50.00N/A
i
12/7/2015Jefferies Financial GroupUpgradeHold ➝ Buy$55.00N/A
i
(Data available from 11/25/2015 forward)
Abbott Laboratories logo
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. Its Established Pharmaceutical Products segment offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon. The company's Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automates the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detects and measures infectious agents; cartridges for blood analysis; rapid diagnostics systems; molecular point-of-care testing for HIV, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test systems, as well as remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. Its Nutritional Products segment provides pediatric and adult nutritional products. The company's Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases, as well as neuromodulation devices for the management of chronic pain and movement disorders. This segment also provides glucose and blood glucose monitoring systems. Abbott Laboratories has an agreement with Tandem Diabetes Care to develop and commercialize integrated diabetes solutions. The company was founded in 1888 and is headquartered in North Chicago, Illinois.
Read More

Today's Range

Now: $107.61
$107.25
$109.59

50 Day Range

MA: $109.61
$105.00
$114.42

52 Week Range

Now: $107.61
$61.61
$115.14

Volume

6,419,808 shs

Average Volume

6,943,608 shs

Market Capitalization

$190.72 billion

P/E Ratio

56.94

Dividend Yield

1.32%

Beta

0.9